Creative Medical Technology Holdings

Creative Medical Technologies, Inc. develops novel regenerative medicine and stem cell technologies. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Its products include CaverStem, FemCelz, StemSpine and ImmCelz. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.

PHOENIX , April 4, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced the filing of its Form 10-K on March 31, 2023 for the year ended December 31, 2022 (FY 2022) and provided a summary of the progress made in 2022 and thus far in 2023. "2022 was a year of significant clinical, regulatory, and partnership milestones, and our efforts in these areas have continued in earnest during 2023," said Timothy Warbington, Chief Executive Officer of Creative Medical Technology.

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

PHOENIX, March 23, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for the treatment of Brittle Type 1 Diabetes using its ImmCelz®(CELZ-100) platform. The ImmCelz® (CELZ-100) immunotherapy product utilizes the  Company's cell-free system which has previously been validated to supercharge the patient's own cells to treat a number of immune disorders.

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Independent Studies Validate Enhanced Clinical Grade Cell Production for Patient Use in Multiple Indications at a Fraction of Current Industry Cost PHOENIX , March 21, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced third party validation regarding several aspects of its  ImmCelz® (CELZ-100) development program, the Company's cell-free system which has previously been validated to supercharge a patient's own cells to treat a number of immune disorders.   These independent studies demonstrated:  a 400% increase in the clinical grade cell production yield at the same cost profile as the Company's first generation ImmCelz line; functional suppression of effector T cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells; and the ability to verify repeated potency of the final ImmCelz®(CELZ-100) product.

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Syneos Health

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced positive three-year follow-up data for the Company's StemSpine® pilot study.

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Creative Medical (NASDAQ: CELZ ) stock is rocketing higher on Wednesday thanks to clearance for a new clinical trial. That clearance comes from the FDA and covers CELZ-201 cell therapy.

Why Is Creative Medical (CELZ) Stock Up 121% Today?

Geovax Labs

NeuroSense Therapeutics Ltd

Quantum Computing

Zhongchao

Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 5 To Watch After News This Week

Company reaches next clinical trial milestone for treatment of Type 1 Diabetes with the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States PHOENIX , Feb. 8, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy. The U.S. Food and Drug Administration (FDA) had previously cleared the Company's Investigational New Drug (IND) application within 30 days from submission.

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

AlloStem™ represents the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States   PHOENIX , Nov. 3, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), an immuno-endocrine company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™. AlloStem™ leverages a unique approach to harnessing the power of Perinatal Tissue Derived Cells® (PRDC) to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion.

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

PHOENIX , Oct. 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem™, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration. "The importance of the company creating and developing such assets, as opposed to licensing agreements with third parties, provides further de-risking of an important component to many of our programs, including, but not limited to, the ImmCelz® immunotherapy platform for multiple diseases, OvaStem® for Premature Ovarian Failure, AlloStem™ for Type 1 diabetes, StemSpine® for lower back pain, and IPSCelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences," said Timothy Warbington, CEO.

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating Chronic Lower Back Pain -- PHOENIX , Sept. 26, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine® study, showing significant efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Three-Year Follow Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients receiving OvaStem® Procedure for Treating Primary Ovarian Insufficiency PHOENIX , July 28, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company's OvaStem® pilot study.  The data shows significant efficacy of the OvaStem® procedure for the treatment of medical refractory Primary Ovarian Insufficiency (POI) without any serious adverse effects and the successful birth of healthy babies.

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Evofem Biosciences Inc

Ricebran Technologies

Are these penny stocks on your watchlist right now? The post Penny Stocks to Watch as June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Watch as June Comes to an End

PHOENIX , June 15, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell (iPSC) pipeline for the Company's ImmCelz® platform. This project will be identified as iPScelzTM for future reference.

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

PHOENIX , April 29, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 7,555,556 shares of common stock (or common stock equivalents) in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investors unregistered warrants to purchase up to an aggregate of 15,111,112 shares of common stock.

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aterian

Athersys

Clever Leaves Holdings Inc

CYREN

Enservco

ION Geophysical

Alaunos Therapeutics

Short squeeze penny stocks to watch. The post Penny Stocks To Buy?

Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now

Short squeeze penny stocks to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 5 Short Squeeze Stocks To Watch

-- Initial experiments demonstrate expeditious potential for high-volume production of ImmCelz® with consistent potency -- PHOENIX , April 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ImmCelz® product was produced in less than 72 hours, utilizing the Company's cell-free supercharging solution.

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

PHOENIX , April 12, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology and orthopedics, today announced that it will be exhibiting at the American Urological Association ("AUA") Annual Meeting on May 13-16, 2022 in New Orleans to showcase CaverStem®, the only patented procedure performed by a licensed physician that provides a safe, effective solution to treat erectile dysfunction using the patient's own stem cells to repair damaged tissue. "With the addition of team members with decades of experience in medicine and medical marketing, we are excited to present CaverStem® to this very prominent group of practicing physicians.

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

IZEA

Mullen Automotive

Check these three trending penny stocks out for your watchlist right now The post Trending Penny Stocks to Buy Now, 3 to Watch During Trading in April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks to Buy Now, 3 to Watch During Trading in April

Grom Social Enterprises

VEON

Are these penny stocks on your April watchlist? The post Best Penny Stocks to Buy as March Ends?

Best Penny Stocks to Buy as March Ends? 3 For Your List

Eos Energy Enterprises

iBio

Rigel Pharmaceuticals

Here's what you need to know about trading penny stocks in April The post How to Trade Penny Stocks in April 2022 and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Trade Penny Stocks in April 2022 and 3 to Watch

ADMA Biologics

Agrify

Are these penny stocks on your April watchlist? The post Top Must-Watch Penny Stocks For Your April List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Must-Watch Penny Stocks For Your April List

Creative Medical Technology (CELZ) reports positive follow-up data from a pilot study evaluating StemSpine, a patented stem cell treatment for chronic lower back pain.

Creative Medical (CELZ) Up 82% on Stem Cell Treatment Data

Creative Medical Technology announced positive results concerning its StemSpine procedure. Here's what you should know as CELZ stock rises.

Why Is Creative Medical Technology (CELZ) Stock Up Today?

News for Creative Medical Technology Holdings Stock (CELZ)